The healthcare enterprise Centene Corp. and Washington University School of Medicine in St. Louis are collaborating to speed research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity.
These common, debilitating and sometimes deadly diseases affect millions of people worldwide, at all income levels. As part of the partnership, Centene will fund up to $100 million over 10 years in research at Washington University, helping to galvanize the School of Medicine’s Personalized Medicine Initiative, which aims to develop customized disease treatment and prevention for patients.
Innovations arising from the initiative will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene. Reflecting the philosophy of both institutions, ARCH is designed to accelerate the development and implementation of affordable and accessible health solutions to the public, using the intellectual property developed from this research.